2. Disease Areas
  3. Infection
  4. Parasitic Infection
  5. Leishmania Infection

Leishmania Infection

Leishmaniasis is a group of diseases caused by parasitic protozoa of the genus Leishmania, transmitted to humans and other vertebrates through the bites of infected sand flies. These intracellular parasites undergo a complex life cycle, alternating between a flagellated promastigote stage in the sand fly vector and an amastigote form within mammalian host cells, primarily macrophages. After transmission during blood feeding, promastigotes are phagocytosed by mononuclear phagocytes, where they differentiate into amastigotes that replicate intracellularly, leading to cell rupture and dissemination to new host cells, including dendritic cells and fibroblasts. The disease manifests in various clinical forms—cutaneous, mucosal, and visceral—depending on the species involved and host immune responses. Leishmaniasis remains a significant global health concern, with an estimated 12 million people currently infected and 2 million new cases reported annually. Its increasing prevalence is driven by factors such as the HIV/AIDS epidemic, international travel, limited vaccine availability, challenges in vector control, conflict-related displacement, and growing resistance to antileishmanial drugs.

References:

Leishmania Infection (39):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108610A
    Edelfosine 70641-51-9 99.0%
    Edelfosine (ET-18-OCH3) is an orally active lipid raft modulator and apoptosis inducer that alters membrane fluidity and preferentially inserts into tumor cell membranes. Edelfosine recruits death receptor ligands (FasL/CD95L, TRAIL) and Bid to lipid rafts to form death-inducing signaling complexes, thereby initiating mitochondria-dependent apoptosis and inducing cytochrome c release. Edelfosine also exerts anti-inflammatory effects, promotes L-Selectin shedding, and causes no gastrointestinal or organ toxicity. In addition, Edelfosine inhibits nucleic acid and protein synthesis in Leishmania donovani and exhibits antiproliferative activity. Edelfosine can be used in research on multiple myeloma, inflammatory bowel diseases (such as ulcerative colitis and Crohn's disease), and visceral leishmaniasis.
    Edelfosine
  • HY-W016813
    trans-Aconitic acid 4023-65-8 99.74%
    trans-Aconitic acid is an orally active aconitase inhibitor that non-competitively inhibits the conversion of citric acid to cis-aconitic acid and competitively inhibits the conversion of cis-aconitic acid to isocitric acid. trans-Aconitic acid inhibits the growth of Leishmania donovani promastigotes, the transformation of Leishmania donovani amastigotes to promastigotes, and the in vitro proliferation of Leishmania donovani amastigotes within macrophages in vitro. trans-Aconitic acid can be used in research related to visceral leishmaniasis (kala-azar).
    trans-Aconitic acid
  • HY-76228
    1H-pyrazole 288-13-1 99.78%
    1H-pyrazole (Pyrazole) is a five-membered heterocyclic compound, and its derivatives are orally effective antimalarial and antileishmanial agents with the potential to modulate targets such as alcohol dehydrogenase and NMDA receptors. 1H-pyrazole derivatives exhibit inhibitory effects on Plasmodium berghei in infected mice and on promastigotes of Leishmania aethiopica, respectively. 1H-pyrazole can be used in research related to malaria and leishmaniasis.
    1H-pyrazole
  • HY-W039443
    (S)-4-Thiazolidinecarboxylic acid 45521-09-3
    (S)-4-Thiazolidinecarboxylic acid (L-4-thioproline) is a glutamate 5-kinase inhibitor with an IC50 of 1.8 mM against LdG5K. (S)-4-Thiazolidinecarboxylic acid can be used in the research of leishmaniasis and Escherichia coli infections.
    (S)-4-Thiazolidinecarboxylic acid
  • HY-N7926
    Pentadecane 629-62-9 98.88%
    Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis.
    Pentadecane
  • HY-N19832
    Icariside E3 117613-74-8
    Icariside E3 is a Leishmania donovani DNA Topoisomerase IB (LdTOP1LS) inhibitor. Icariside E3 can be used for the research of leishmaniasis.
    Icariside E3
  • HY-183262
    Antileishmanial agent-40
    Antileishmanial agent-40 is an orally active and selective antileishmanial agent. Antileishmanial agent-40 elevates intracellular reactive oxygen species (ROS) levels in Leishmania donovani promastigotes. Antileishmanial agent-40 induces cell cycle arrest at the sub-G0/G1 phase in Leishmania donovani promastigotes, indicative of programmed-like parasite death. Antileishmanial agent-40 can be used for the research of leishmaniasis.
    Antileishmanial agent-40
  • HY-177958
    ACS03 2227022-64-0
    ACS03 is a hybrid thiophene-acridine compound. ACS03 induces an increase in lactate dehydrogenase, glutathione S-transferase, and AChE activities. ACS03 has antileishmanial activity. ACS03 exhibits selective anti-cancer effects against colon carcinoma.
    ACS03
  • HY-162066
    DNDI-6174 2868298-43-3
    DNDI-6174 is an orally active Leishmania cytochrome b (Qi site of cytochrome bc1 complex/complex III) inhibitor. DNDI-6174 binds to the Qi site of Leishmania cytochrome b, inhibits cytochrome bc1 complex activity in the parasite's electron transport chain across promastigote and axenic amastigote stages. DNDI-6174 reduces parasite burden in rodent models, inhibits growth of various Leishmania species, drug-resistant clinical isolates, and Trypanosoma cruzi, with marginal activity against Trypanosoma brucei. DNDI-6174 can be used for the research of visceral leishmaniasis, cutaneous leishmaniasis.
    DNDI-6174
  • HY-W001119
    6-Hydroxyindazole 23244-88-4
    6-Hydroxyindazole is an anti-parasite agent with an EC50 of 128.9 μM against intracellular amastigotes of Leishmania amazonensis. 6-Hydroxyindazole can be used in the research of leishmaniasis.
    6-Hydroxyindazole
  • HY-N7926S
    Pentadecane-d32 36340-20-2 99.2%
    Pentadecane-d32 is the deuterium labeled Pentadecane (HY-N7926). Pentadecane is an orally active natural plant volatile alkane with anti-inflammatory, analgesic, antipyretic and anti-leishmanial activities. Pentadecane presents IC50 values of 65.3 μM, 60.5 μM and 194.8 μM against Leishmania infantum promastigotes, amastigotes and intracellular amastigotes, respectively. Pentadecane downregulates the mRNA expression of TNF-α and IL-12 and inhibits the release of inflammatory mediators. Pentadecane arrests the cell cycle of Leishmania infantum and induces apoptosis. Pentadecane can be applied to the research of inflammation and leishmaniasis.
    Pentadecane-d<sub>32</sub>
  • HY-N4267
    Yangambin 13060-14-5 98.27%
    Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases.
    Yangambin
  • HY-134467
    Phylloflavan 98570-83-3
    Phylloflavan is an antileishmanial (Antileishmanial) agent with an EC50 of 3.2 nM against intracellular amastigotes of Leishmania donovani. Phylloflavan is isolated from Phyllocldus plants. Phylloflavan induces moderate levels of NO release. Phylloflavan also inhibits the cytopathic effect of encephalomyocarditis virus on L929 fibroblasts (38 U/mL).
    Phylloflavan
  • HY-183362
    Antileishmanial agent-42
    Antileishmanial agent-42 is an antileishmanial agent. Antileishmanial agent-42 has favorable interactions with key active site residues (e.g., Ser63, Asn66/295/299) of adenosine kinase. Antileishmanial agent-42 exerts activity against promastigote and amastigote forms of L. amazonensis, L. braziliensis, L. infantum, and L. donovani.
    Antileishmanial agent-42
  • HY-183290
    Antileishmanial agent-41
    Antileishmanial agent-41 (Compound 20k) is a selective Antileishmanial agent with a IC50 of 1.51 μg/mL against Leishmania donovani. Antileishmanial agent-41 increases ROS levels. Antileishmanial agent-41 can be used for the research of leishmaniasis.
    Antileishmanial agent-41
  • HY-N19720
    Bractein 22684-08-8
    Bractein is a natural aurone flavonoid with potential antioxidant activity. Bractein shows in vitro antileishmanial activity and inhibits promastigotes and intracellular amastigotes of Leishmania donovani. Bractein exhibits no obvious cytotoxicity against mammalian macrophages with an EC50 value > 25.0 μg/mL. Bractein can be used for the research of Leishmania.
    Bractein
  • HY-W663179
    DNDI-VL-2098 681492-17-1
    DNDI-VL-2098 is an orally active antileishmanial agent. DNDI-VL-2098 exhibits high permeability, in vitro metabolic stability, and selective inhibition of CYP2C19 (IC50=0.47 μM). DNDI-VL-2098 does not affect the activities of other major CYP enzymes (CYP1A2, CYP2C9, CYP2D6 and CYP3A4) at concentrations up to 12.5 μM. It shows favorable pharmacokinetic properties in multiple animal models including mice, hamsters, rats and dogs. DNDI-VL-2098 is characterized by moderate to high plasma protein binding and can be used for the research of visceral leishmaniasis.
    DNDI-VL-2098
  • HY-19719B
    Miransertib mesylate 1817727-88-0
    Miransertib (ARQ-092) mesylate is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib mesylate is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research. Miransertib mesylate is effective against Leishmania.
    Miransertib mesylate
  • HY-N17550
    25-Hydroperoxycycloart-23-en-3β-ol 173740-54-0
    25-Hydroperoxycycloart-23-en-3β-ol is an anticancer, antibacterial, and antimalarial agent. 25-Hydroperoxycycloart-23-en-3β-ol can be isolated from Blepharodon nitidum. 25-Hydroperoxycycloart-23-en-3β-ol exhibits anti-Mycobacterium tuberculosis and antileishmanial activities. 25-Hydroperoxycycloart-23-en-3β-ol shows significant cytotoxic activity against a panel of tumor cell lines (large cell lung cancer, melanoma, colon adenocarcinoma, chronic myelogenous leukemia).
    25-Hydroperoxycycloart-23-en-3β-ol
  • HY-B1509A
    Trypaflavin 86-40-8
    Trypaflavin is an acridine compound and antimalarial agent. Trypaflavin invades germ cells. Trypaflavin induces aberrations in unfertilized oocytes. Trypaflavin increases the frequency of chromosomal aberrations. Trypaflavin shows weak mutagenicity. Trypaflavin is highly toxic to Leishmania, causing immediate lysis of the leptomonads.
    Trypaflavin